FY2026 Earnings Estimate for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Issued By Zacks Research

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 3rd. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will post earnings per share of $16.03 for the year, up from their previous forecast of $15.97. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $14.95 per share.

A number of other equities research analysts also recently issued reports on VRTX. Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Barclays upped their target price on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 6th. Finally, Wolfe Research started coverage on Vertex Pharmaceuticals in a research note on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $420.48.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $406.67 on Friday. The firm has a 50 day simple moving average of $419.77 and a 200 day simple moving average of $393.86. Vertex Pharmaceuticals has a 52 week low of $316.43 and a 52 week high of $448.40. The stock has a market cap of $105.05 billion, a P/E ratio of 29.28, a P/E/G ratio of 2.20 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the prior year, the business earned $3.33 EPS.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. LSV Asset Management grew its holdings in shares of Vertex Pharmaceuticals by 206.3% during the 1st quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock worth $1,240,000 after purchasing an additional 3,200 shares in the last quarter. Synovus Financial Corp boosted its stake in Vertex Pharmaceuticals by 9.6% during the first quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock worth $1,759,000 after buying an additional 590 shares in the last quarter. Cibc World Market Inc. increased its holdings in Vertex Pharmaceuticals by 69.4% in the 1st quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock valued at $1,728,000 after buying an additional 2,713 shares during the period. Sei Investments Co. raised its stake in shares of Vertex Pharmaceuticals by 28.4% in the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock valued at $11,756,000 after buying an additional 9,761 shares in the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of Vertex Pharmaceuticals by 4.0% during the 1st quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after acquiring an additional 544 shares during the period. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. Insiders sold 19,029 shares of company stock worth $7,989,227 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.